Syros Pharmaceuticals Inc. (SYRS)

Syros Pharmaceuticals Inc. Borsa (SYRS) Ultime notizie

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to Post FY2025 Earnings of ($0.77) Per Share, Brookline Capital ... - MarketBeat

MarketBeat

Syros Pharmaceuticals, Inc. Forecasted to Post FY2026 Earnings of $1.62 Per Share (NASDAQ:SYRS) - MarketBeat

MarketBeat

Syros Pharmaceuticals (NASDAQ:SYRS) Earns "Buy" Rating from HC Wainwright - MarketBeat

MarketBeat

Syros Pharmaceuticals (NASDAQ:SYRS) Announces Earnings Results - MarketBeat

MarketBeat

Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic Developments and ... - GuruFocus.com

GuruFocus.com

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire

Business Wire

Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

Short Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Decreases By 22.0% - MarketBeat

MarketBeat

Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Tuesday - Defense World

Defense World

Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

MarketBeat

ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? - Yahoo Singapore News

Yahoo Singapore News

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

MarketBeat

Syros to Participate in Upcoming Investor Conferences - Business Wire

Business Wire

What Did Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Take Home Last Year? - Yahoo New Zealand News

Yahoo New Zealand News

Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Crosses Below 50-Day Moving Average of $5.94 - MarketBeat

MarketBeat

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research

Zacks Investment Research

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates

Zacks Investment Research

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Yahoo Finance

Syros Pharmaceuticals (NASDAQ:SYRS) Shares Pass Below 50 Day Moving Average of $6.38 - MarketBeat

MarketBeat

Cyclin Dependent Kinase 7 Market Analysis | Beta Pharma Inc, Cyclacel Pharmaceuticals Inc, Qurient Co Ltd, Syros ... - Currency News Centre

Currency News Centre

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Zacks Investment Research

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros ... - Yahoo Finance

Yahoo Finance

Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News

Zacks Investment Research

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

Zacks Investment Research

Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?

Zacks Investment Research

Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? - Yahoo Finance Australia

Yahoo Finance Australia

Crude Oil Down Over 1%; Cognyte Software Shares Plummet

Benzinga

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit ... - Business Wire

Business Wire

Top 3 Health Care Stocks You'll Regret Missing This Month

Benzinga

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON - Benzinga

Benzinga

Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations - Yahoo Finance

Yahoo Finance

Syros enrols subjects in myelodysplastic syndrome drug trial - Clinical Trials Arena

Clinical Trials Arena

SYRS Stock Quote Price and Forecast - CNN

CNN

Painful week for private equity firms invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) after 11% drop, institutions also suffered losses - Simply Wall St

Simply Wall St

Syros to Participate in TD Cowen 44th Annual Health Care Conference - Business Wire

Business Wire

Long Term Trading Analysis for (SYRS) - Stock Traders Daily

Stock Traders Daily

Thinking about buying stock in Biofrontera, Snowflake, Syros Pharmaceuticals, Agenus, or Kopin? - Marketscreener.com

Marketscreener.com

Thinking about buying stock in Rivian Automotive, Bitdeer Technologies, Syros Pharmaceuticals, Lucid Group, or Ayr ... - Marketscreener.com

Marketscreener.com

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

Zacks Investment Research

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why - Nasdaq

Nasdaq

Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice

Zacks Investment Research

Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance

Yahoo Finance

What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock

Zacks Investment Research